First-line ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study

Azim, H. A.; El Saghir, N. S.; Yap, Y. S.; Eralp, Y.; Im, S\\-A.; Sandhu, M. S.; Abdel\\-Razeq, H.; Gupta, S.; Artamonova, E.; Rihani, J.; Alfaro, T. Delgar; Wu, J.; Hu, H.; Gao, M.; Lu, Y\\-S.

doi:10.1016/j.annonc.2023.09.579

First-line ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study

Date

2023

Authors

dc.identifier.doi

10.1016/j.annonc.2023.09.579

dc.identifier.other

WOS:001087480200391

Publisher

ELSEVIER

DOI

10.1016/j.annonc.2023.09.579

Abstract

Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid, SPAIN, OCT 20-24, 2023

URI

https://openaccess.acibadem.edu.tr/handle/11443/6158

Collections

WOS

Full item page

First-line ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without visceral crisis from the phase II RIGHT choice study

Date

Authors

Journal Title

Journal ISSN

Volume Title

dc.identifier.issn

dc.identifier.doi

dc.identifier.other

dc.description.volume

dc.description.issue

Publisher

DOI

Abstract

Description

Keywords

Citation

URI

Collections

Endorsement

Review

Supplemented By

Referenced By